Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 50

1.

Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study.

Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O'Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF; NHLBI Heart Failure Clinical Research Network..

Circulation. 2015 May 19;131(20):1763-71. doi: 10.1161/CIRCULATIONAHA.114.014536.

2.

Cardiorenal metabolic syndrome and cardiometabolic risks in minority populations.

Ferdinand KC, Rodriguez F, Nasser SA, Caballero AE, Puckrein GA, Zangeneh F, Mansour M, Foody JM, Pemu PE, Ofili EO.

Cardiorenal Med. 2014 Apr;4(1):1-11. doi: 10.1159/000357236. Review.

3.

Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.

Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart BA, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O'Meara E, Tang WH, Starling RC, Butler J, Deswal A, Felker GM, O'Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Dávila-Román VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM; NHLBI Heart Failure Clinical Research Network..

JAMA. 2013 Dec 18;310(23):2533-43. doi: 10.1001/jama.2013.282190.

4.

Models of interinstitutional partnerships between research intensive universities and minority serving institutions (MSI) across the Clinical Translational Science Award (CTSA) consortium.

Ofili EO, Fair A, Norris K, Verbalis JG, Poland R, Bernard G, Stephens DS, Dubinett SM, Imperato-McGinley J, Dottin RP, Pulley J, West A, Brown A, Mellman TA.

Clin Transl Sci. 2013 Dec;6(6):435-43. doi: 10.1111/cts.12118.

5.

Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E; RELAX Trial..

JAMA. 2013 Mar 27;309(12):1268-77. doi: 10.1001/jama.2013.2024.

6.

Ultrafiltration in decompensated heart failure with cardiorenal syndrome.

Bart BA, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E; Heart Failure Clinical Research Network..

N Engl J Med. 2012 Dec 13;367(24):2296-304. doi: 10.1056/NEJMoa1210357.

7.

Comparative analysis of the efficacy of continuous glucose monitoring and self-monitoring of blood glucose in type 1 diabetes mellitus.

Floyd B, Chandra P, Hall S, Phillips C, Alema-Mensah E, Strayhorn G, Ofili EO, Umpierrez GE.

J Diabetes Sci Technol. 2012 Sep 1;6(5):1094-102. Review.

8.

Early alterations of the immune transcriptome in cultured progenitor cells from obese African-American women.

Pemu PE, Anderson L, Gee BE, Ofili EO, Ghosh S.

Obesity (Silver Spring). 2012 Jul;20(7):1481-90. doi: 10.1038/oby.2011.370.

9.

Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients.

Ofili EO, Zappe DH, Purkayastha D, Samuel R, Sowers JR.

Am J Ther. 2013 Jan;20(1):2-12. doi: 10.1097/MJT.0b013e318230ae66.

10.

Socio-demographic psychosocial and clinical characteristics of participants in e-HealthyStrides©: an interactive ehealth program to improve diabetes self-management skills.

Pemu PE, Quarshie AQ, Josiah-Willock R, Ojutalayo FO, Alema-Mensah E, Ofili EO.

J Health Care Poor Underserved. 2011;22(4 Suppl):146-64. doi: 10.1353/hpu.2011.0162.

11.

The Atlanta Clinical and Translational Science Institute: clinical and translational science education and training partnership.

Stephens DS, West AC, Ofili EO, Boyan BD, Blumberg HM.

Clin Transl Sci. 2011 Jun;4(3):143-5. doi: 10.1111/j.1752-8062.2011.00293.x. No abstract available.

12.

Moderate versus intensive treatment of hypertension using amlodipine/valsartan and with the addition of hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker monotherapy: results in racial/ethnic subgroups.

Ofili EO, Oparil S, Giles T, Pitt B, Purkayastha D, Hilkert R, Samuel R, Sowers JR.

J Am Soc Hypertens. 2011 Jul-Aug;5(4):249-58. doi: 10.1016/j.jash.2011.02.007.

13.
14.

Diuretic strategies in patients with acute decompensated heart failure.

Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O'Connor CM; NHLBI Heart Failure Clinical Research Network..

N Engl J Med. 2011 Mar 3;364(9):797-805. doi: 10.1056/NEJMoa1005419.

15.

Moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy.

Oparil S, Giles T, Ofili EO, Pitt B, Seifu Y, Hilkert R, Samuel R, Sowers JR.

J Hypertens. 2011 Jan;29(1):161-70. doi: 10.1097/HJH.0b013e32834000a7.

16.

Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives.

Sowers JR, Raij L, Jialal I, Egan BM, Ofili EO, Samuel R, Zappe DH, Purkayastha D, Deedwania PC.

J Hypertens. 2010 Aug;28(8):1761-9. doi: 10.1097/HJH.0b013e32833af380.

17.

Fifth Pivotal Research in Cardiology in the Elderly (PRICE-V) Symposium: Preventive Cardiology in the Elderly--executive summary. Part II: afternoon session.

Rich MW, Mensah GA; PRICE-V Investigators..

Prev Cardiol. 2010 Winter;13(1):42-7. doi: 10.1111/j.1751-7141.2009.00047.x. No abstract available.

18.

Fifth Pivotal Research in Cardiology in the Elderly (PRICE-V) symposium: preventive cardiology in the elderly-executive summary. Part I: morning session.

Rich MW, Mensah GA; PRICE-V Investigators..

Prev Cardiol. 2009 Fall;12(4):198-204. doi: 10.1111/j.1751-7141.2009.00048.x. No abstract available.

19.

Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial.

Chrysant SG, Neutel JM, Ferdinand KC; INCLUSIVE investigators..

J Natl Med Assoc. 2009 Apr;101(4):300-7.

PMID:
19397219
20.

Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women: the inclusive trial.

Ofili EO, Cable G, Neutel JM, Saunders E.

J Womens Health (Larchmt). 2008 Jul-Aug;17(6):931-8. doi: 10.1089/jwh.2008.0499.

Items per page

Supplemental Content

Loading ...
Support Center